In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024.

Under the agreement, Neomorph will receive an undisclosed upfront payment from AbbVie and be eligible for up to $1.64 billion in aggregate option fees and milestones.

The company also plans to record a non-cash after-tax impairment charge of approximately $3.5 billion related to the emraclidine intangible asset, due to unsuccessful trials of emraclidine ...

So is the stock worth buying today? AbbVie had a recent setback in November when it announced poor phase 2 study results for emraclidine. The once-promising drug was a potential blockbuster for ...

The company also plans to record a non-cash after-tax impairment charge of approximately $3.5 billion related to the emraclidine intangible asset, due to unsuccessful trials of emraclidine, a drug ...

Shares in AbbVie have slumped after a pair of failed phase 2 trials for emraclidine, a schizophrenia drug it acquired as part of its $8.7 billion takeover of Cerevel Therapeutics last year.